Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer
This real-world study highlights the importance of survivorship care in the era of improved outcomes for ovarian cancer. Continued long-term hematologic monitoring, along with the collection of more cases, is essential to elucidate risk factors for t-MNs in patients receiving PARPi therapy.
Authors
- Shiro Suzuki
- Ryosuke Uekusa
- Katsuhiko Mizuno
- Akira Yokoi (ORCID: https://orcid.org/0000-0003-0789-5102)
- Kosuke Yoshida (ORCID: https://orcid.org/0000-0002-8603-4724)
- Mikako Inoue
- Nobuhisa Yoshikawa
- Eri Watanabe
- Hiroaki Kajiyama
- Kaoru Niimi
Institutions
- Aichi Cancer Center (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-29
- DOI
- https://doi.org/10.3389/fonc.2026.1728766
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Princess Takamatsu Cancer Research Fund
- Japan Society for the Promotion of Science